Original Article

You have full text access to this OnlineOpen article

Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment

  1. Cristianne Tomiyama1,
  2. Aluizio B Carvalho1,
  3. Andrea Higa1,
  4. Vanda Jorgetti2,
  5. Sérgio A Draibe1,
  6. Maria Eugênia F Canziani1,*

Article first published online: 18 MAR 2010

DOI: 10.1359/jbmr.090735

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 3, pages 499–504, March 2010

Additional Information

How to Cite

Tomiyama, C., Carvalho, A. B., Higa, A., Jorgetti, V., Draibe, S. A. and Canziani, M. E. F. (2010), Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res, 25: 499–504. doi: 10.1359/jbmr.090735

Author Information

  1. 1

    Department of Internal Medicine, Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil

  2. 2

    Department of Internal Medicine, Division of Nephrology, University of São Paulo, São Paulo, Brazil

*Rua Pedro de Toledo, 282 CEP 04039-000, São Paulo, SP, Brazil.

Publication History

  1. Issue published online: 18 MAR 2010
  2. Article first published online: 18 MAR 2010
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 9 JUL 2009
  5. Manuscript Revised: 11 MAR 2009
  6. Manuscript Received: 9 SEP 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (125K)

References

  • 1
    Elhajj II, Haydar AA, Hujairi NM, Goldsmith DJ. The role of inflammation in acute coronary syndromes: review of the literature. J Med Liban. 2004; 52: 96–102.
  • 2
    Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol. 2005; 16: 507–513.
  • 3
    London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18: 1731–1740.
  • 4
    Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438–441.
  • 5
    Mehrotra R. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. J Ren Nutr. 2006; 16: 100–118.
  • 6
    Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999; 100: 2168–2176.
  • 7
    Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478–1483.
  • 8
    Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003; 14: 159–168.
  • 9
    Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int. 2004; 65: 1790–1794.
  • 10
    Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int. 2005; 67: 1576–1582.
  • 11
    Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis. 2004; 44: 1024–1030.
  • 12
    Tomiyama C, Higa A, Dalboni MA, et al. The impact of traditional and nontraditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant. 2006; 21: 2464–2471.
  • 13
    Porter CJ, Stavroulopoulos A, Roe SD, Pointon K, Cassidy MJ. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2007; 22: 3208–3213.
  • 14
    K/DOQI. clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: S1–201.
  • 15
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827–832.
  • 16
    Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595–610.
    Direct Link:
  • 17
    Dos Reis LM, Batalha JR, Munoz DR, et al. Brazilian normal static bone histomorphometry: effects of age, sex, and race. J Bone Miner Metab. 2007; 25: 400–406.
  • 18
    Melsen F, Mosekilde L. Tetracycline double-labeling of iliac trabecular bone in 41 normal adults. Calcif Tissue Res. 1978; 26: 99–102.
  • 19
    K/DOQI. clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1–266.
  • 20
    Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002; 39: 695–701.
  • 21
    Stompor T, Pasowicz M, Sullowicz W, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis. 2003; 41: 203–211.
  • 22
    Barreto DV, Barreto FdC, Carvalho ABd, et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis. 2008: (in press).
  • 23
    London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943–1951 .
  • 24
    F.L J.B, Renal osteodystrophies. In: BMB, ed. The Kidney. Philadelphia: Saunders; 2000; 2103–2186.
  • 25
    Solal ME, Sebert JL, Boudailliez B, et al. Comparison of intact, midregion, and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991; 73: 516–524.
  • 26
    Coen G, Ballanti P, Bonucci E, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002; 91: 103–111.
  • 27
    Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int. 1993; 43: 436–442.
  • 28
    Ingham JP, Stewart JH, Posen S. Quantitative skeletal histology in untreated end-stage renal failure. Br Med J. 1973; 2: 745–748.
  • 29
    Hutchison AJ, Whitehouse RW, Boulton HF, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993; 44: 1071–1077.
  • 30
    Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant. 1994; 9: 517–523.
  • 31
    Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003; 18: 1159–1166.
  • 32
    Yano S, Yamaguchi T, Kanazawa I, et al. The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. Nephrol Dial Transplant. 2007; 22: 3160–3165.
  • 33
    Picton ML, Moore PR, Mawer EB, et al. Downregulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000; 58: 1440–1449.
  • 34
    Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000; 58: 753–761.
  • 35
    Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab. 1992; 75: 145–150.
  • 36
    Davies MR, Lund RJ, Mathew S, Hruska KA. Low-turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol. 2005; 16: 917–928.
  • 37
    Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003; 17: 2393–2403.
  • 38
    Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008; 23: 939–948.
    Direct Link:
  • 39
    Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF 23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561–568.
  • 40
    Jehle PM, Ostertag A, Schulten K, et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int. 2000; 57: 423–436.
  • 41
    Wang S, Chen Q, Simon TC, et al. Bone morphogenic protein 7 (BMP-7), a novel therapy for diabetic nephropathy1. Kidney Int. 2003; 63: 2037–2049.
  • 42
    Andress DL, Pandian MR, Endres DB, Kopp JB. Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism. Kidney Int. 1989; 36: 471–477.
  • 43
    Jena N, Martin-Seisdedos C, McCue P, Croce CM. BMP7-null mutation in mice: developmental defects in skeleton, kidney, and eye. Exp Cell Res. 1997; 230: 28–37.
  • 44
    Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW. Bone loss and the progression of abdominal aortic calcification over a 25year period: the Framingham Heart Study. Calcif Tissue Int. 2001; 68: 271–276.
  • 45
    Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000; 20: 1926–1931 .
  • 46
    Frost M, Grella R, Millasseau S, et al. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int. 2008: (in press).
  • 47
    Hsia J, Klouj A, Prasad A, Burt J, Adams-Campbell L, Howard B. Progression of coronary calcification in healthy postmenopausal women. BMC Cardiovasc Disord. 2004; 4: 21.
  • 48
    Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996; 27: 394–401.
  • 49
    Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46: 855–861.
  • 50
    Dusso AS, Brown AJ, Slatopolsky E, Vitamin D. Am J Physiol Renal Physiol. 2005; 289: F8–28.
View Full Article (HTML) Get PDF (125K)